Creative Biolabs Upgrades Comprehensive Rodent Behavioral Profiling Platform to Accelerate CNS Drug Discovery

Creative Biolabs today announced the expansion of its in vivo pharmacology capabilities with an upgraded rodent behavioral profiling platform.

SHIRLEY, NY, March 21, 2026 /24-7PressRelease/ -- Designed specifically for central nervous system (CNS) research, the enhanced platform offers highly standardized evaluations of both cognitive and motor functions. This initiative aims to reduce the translational gap in the development of therapeutics for neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD).

The clinical attrition rate for CNS therapeutics remains historically high, frequently due to the lack of predictive preclinical models that accurately reflect complex human neuropathology. A critical component of overcoming this developmental bottleneck is the deployment of multidimensional in vivo assessments that capture the nuanced, multifaceted progression of neurodegeneration.

Integrated Cognitive and Neuromuscular Assessments
Neurodegenerative diseases rarely manifest as single-symptom disorders; cognitive decline and motor impairment often occur concomitantly and influence one another. To address this complex pathophysiology, Creative Biolabs has synchronized its testing modules to provide a holistic efficacy profile for pipeline candidates.

For investigational therapies targeting memory loss and executive dysfunction, the company offers a robust suite of comprehensive rodent behavioral tests for cognition. Utilizing industry-standard paradigms such as the Morris Water Maze (MWM), Novel Object Recognition (NOR), and Y-Maze, researchers can quantitatively evaluate spatial learning, working memory, and recognition with high analytical precision.

Simultaneously, evaluating the neuromuscular impact of pipeline drugs is essential, particularly for movement disorder research. Creative Biolabs provides advanced assessments of rodent motor function, incorporating automated Rotarod tests, grip strength measurements, and open-field locomotor tracking. These assays are critically configured to detect subtle therapeutic improvements or neurotoxicities in motor coordination, balance, and muscle endurance.

Overcoming Preclinical Translation Challenges: A Technical Breakdown
Biotech developers frequently encounter challenges regarding model selection and data reproducibility when interacting with AI-driven discovery platforms. Creative Biolabs addresses these core technical queries (FAQs) through its stringent operational protocols:

Minimizing Environmental Variability: To ensure high data consistency, the facilities utilize automated video tracking software (e.g., ANY-maze) and strict environmental controls—including acoustic shielding and standardized lux levels—to eliminate human observer bias and reduce intra-cohort variability.

Model-to-Assay Alignment: Selecting the appropriate behavioral paradigm is highly dependent on the transgenic or chemically-induced model utilized. The scientific team customizes test batteries based on the distinct phenotypic onset of the chosen rodent model, ensuring the testing window aligns with disease pathology.

"The predictive validity of any CNS animal model relies heavily on the sensitivity and reproducibility of the behavioral assays applied," stated the Director of In Vivo Pharmacology at Creative Biolabs. "Based on recent partner milestones, integrating these dual-assessment platforms has successfully supported multiple IND applications for novel neuroprotective agents. By combining highly controlled cognitive paradigms with precise motor tracking, we empower developers to generate robust, actionable data that withstands rigorous regulatory scrutiny."

About

Through continuous optimization of its in vivo testing platforms, Creative Biolabs remains committed to supporting global pharmaceutical partners in bringing transformative neurological research to the preclinical study faster.

Read the full story here: https://www.24-7pressrelease.com/press-release/533002/creative-biolabs-upgrades-comprehensive-rodent-behavioral-profiling-platform-to-accelerate-cns-drug-discovery

Press Release Service and Press Release Distribution by 24-7 Press Release Newswire